Autonomix Medical

Autonomix Medical EV/OCF

The EV/OCF (Enterprise Value to Operating Cash Flow) of Autonomix Medical (AMIX) as of Oct 21, 2026 is 0.21. In the previous year, EV/OCF (Enterprise Value to Operating Cash Flow) was 0.58 — a change of -62.86% (lower).

EV/OCF

0.21

YoY

-62.86%

Last updated:

EV/OCF (Enterprise Value to Operating Cash Flow) of Autonomix Medical is 2026 0.21 . EV/OCF (Enterprise Value to Operating Cash Flow) of Autonomix Medical was 2025 0.58 . It decreases by -62.86% lower compared to the previous year.

The Autonomix Medical EV/OCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/OCF
Date
EV/OCF
Jan 1, 2022
-6.01 USD
Jan 1, 2023
-1.89 USD
Jan 1, 2024
0.49 USD
Jan 1, 2025
0.58 USD
Jan 1, 2026
0.21 USD
The Autonomix Medical EV/OCF history
YEAREV/OCFYoY
0.21-62.86%
0.58+18.60%
0.49-125.70%
-1.89-68.54%
-6.01—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Autonomix Medical Stock analysis

What does Autonomix Medical do? Autonomix Medical Inc develops medical devices focused on treating peripheral nervous system diseases. The company's technology platform features a catheter-based microchip sensing array capable of detecting peripheral neural signals with up to 1,000 times sensitivity. It is developing a dual-function technology that both detects malfunctioning neural signals and ablates nerves in a single procedure for pain management. The company targets conditions like pancreatic cancer and pancreatitis, which cause severe pain requiring effective solutions. Its Autonomix catheter uses a microchip to convert body analog signals into digital signals for direct transmission to a computer. The company's products include the Autonomix catheter and its underlying technology platform. These are designed for medical professionals treating conditions involving the peripheral nervous system. The primary segments served are patients suffering from pancreatic cancer, pancreatitis, and other peripheral nervous system disorders requiring pain management solutions. The technology platform has potential applications across multiple medical fields including cardiology, renal denervation, and chronic pain management. Autonomix Medical Inc's revenue model is based on developing and commercializing its medical device technology. The company is focused on creating solutions for specific medical conditions where current treatments are inadequate. Its dual-function technology represents a novel approach to pain management by combining detection and ablation capabilities in one procedure. The company's target market includes healthcare providers seeking advanced solutions for peripheral nervous system diseases and chronic pain conditions. Autonomix Medical is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Autonomix Medical stock

EV/OCF (Enterprise Value to Operating Cash Flow) of Autonomix Medical is 0.21 in 2026.

EV/OCF (Enterprise Value to Operating Cash Flow) of Autonomix Medical changed from 0.58 to 0.21, representing a -62.86% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/OCF (Enterprise Value to Operating Cash Flow) Autonomix Medical since 2006 – with annual values, charts, and detailed analysis.

EV/OCF compares enterprise value to operating cash flow, measuring how much investors pay per unit of cash generated from operations.

To evaluate EV/OCF (Enterprise Value to Operating Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/OCF (Enterprise Value to Operating Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/OCF (Enterprise Value to Operating Cash Flow)'s Autonomix Medical with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Autonomix Medical

All Key Metrics — Autonomix Medical